Australia allows PCT national phase entry up to 31 months from the earliest priority date. IP Australia requires national-phase instructions, details of the PCT application, an Australian address for service, the entry fee and a verified English translation where needed.
| Patent office | IP Australia |
|---|---|
| Entry deadline | 31 months from the earliest priority date. |
| Language / translation | A verified English translation is required where the PCT application was filed in another language. |
| Representation | IP Australia requires an Australian address for service; applicants should confirm current representation and service requirements for their filing circumstances. |
| Portfolio question | Australia can be strategically important for medtech, mining, energy, software, biotech, agriculture and Asia-Pacific commercialization. |
This page separates current office procedure from filing strategy. Deadlines, fees and office requirements can change, so consequential filing decisions should be checked against the official sources listed below.
IP Australia states that applicants have up to 31 months from the earliest priority date to enter the Australian national phase. That extra month beyond the standard 30-month PCT period should not become a reason to delay preparation. Translation, address-for-service details, claim review and commercial reassessment should begin earlier.
IP Australia identifies several core requirements: the applicant must indicate the intention to enter the national phase, provide details of the relevant PCT application, provide an Australian address for service and pay the national-phase entry fee. If the PCT application was not in English, a verified English translation is also required.
Where the international application is not in English, IP Australia requires a verified English translation. Technical terminology should be checked carefully because later Australian prosecution will rely on the filed national-phase record. Translation quality matters especially in chemistry, biotech, software and engineering cases where wording can affect support and claim scope.
IP Australia expressly notes that a clear international preliminary report does not automatically result in Australian grant, and a clear report is not required to enter the national phase. Australian examination remains independent and applies Australian patent law.
The national-phase entry fee is not itself an examination fee. Examination is a separate stage and should be planned with the applicant’s product timeline, funding and enforcement objectives. Early commercial events may justify earlier prosecution planning.
An Australian address for service is part of the national-phase requirements identified by IP Australia. Foreign applicants should coordinate this requirement with any Australian patent professional they intend to use so filing instructions are complete well before the deadline.
Australia can matter for medical technology, mining, clean energy, agriculture, software, biotech, advanced manufacturing and consumer markets. Its role should be evaluated against other Asia-Pacific jurisdictions rather than included automatically in every global portfolio.
Australia’s costs can include the national-phase entry fee, translation where required, professional services, examination, prosecution responses and renewal fees. Applicants should distinguish the relatively predictable entry-stage cost from the more uncertain prosecution and lifecycle costs.
Retain Australia where the market, local commercialization, R&D, licensing, competitor activity or enforcement value justifies the cost. A favorable PCT search can support the decision, but the commercial reason for filing should remain explicit.
Before entering the national phase in Australia, re-check the controlling deadline, translation requirements, required application documents, representation rules, official fees and any available restoration or extension mechanism against the current patent-office or WIPO materials linked on this page. A national-phase decision should also confirm that the application being entered is the correct international application and that the claims, description and drawings support the commercial product. Procedural accuracy and portfolio value are separate questions, so both should be reviewed before fees are committed.
Entry into Australia should be tied to a commercial reason. Relevant evidence can include expected revenue, manufacturing, technically significant infrastructure, competitors, licensees, investors, regulated-market access and the location of acts that could support infringement evidence. A large market is not automatically a high-value patent market for every invention. The strongest decision record states what commercial leverage the right is expected to create and what portfolio cost will be required through prosecution and maintenance.
The PCT application may contain broad claims, but the commercially useful position in Australia can depend on who performs the claimed steps and how the product is deployed. Server-side, device, system, composition, method or manufacturing claims can create different enforcement positions depending on the technology. Before examination begins, identify the product features that matter, the likely competitor implementation and the evidence that could later show use of the claimed invention.
The national-phase deadline is not only a procedural event. It is a natural point to review product-market fit, licensing discussions, competitor activity, financing, technical changes and prior-art developments. If the invention has changed materially since the priority filing, prosecution strategy should be adjusted within the support available in the original disclosure. Jurisdictions that no longer support a clear business objective can be removed, allowing budget to move toward stronger markets or newer inventions.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Use current official requirements together with market, technology, manufacturing, licensing, competitor and enforcement considerations before committing to long-term portfolio cost.
rd (at) patentbusinesslawyer (dot) com
This national-phase guide explains entering the jurisdiction. For the separate question of taking an invention originating here into foreign markets, Read the origin-country international filing guide.
